Loading clinical trials...
Loading clinical trials...
A Global, Multi-center, Randomized, Double-Blind, Placebo-controlled, Phase III Clinical Study to Evaluate the Protective Efficacy, Safety and Immunogenicity of SARS-CoV-2 Messenger Ribonucleic Acid (mRNA) Vaccine in Population Aged 18 Years and Older
Conditions
Interventions
SARS-CoV-2 mRNA Vaccine
Placebo
Locations
12
Indonesia
Persahabatan Hospital
Jakarta, Indonesia
Puskesmas Duren Sawit
Jakarta, Indonesia
Puskesmas Kalideres
Jakarta, Indonesia
Puskesmas Kebayoran Lama
Jakarta, Indonesia
Puskesmas Pulogadung
Jakarta, Indonesia
Centro de Investigación Clínica del Pacifico S.A. de C.V. (CICPA)
Acapulco, Mexico
Start Date
July 22, 2021
Primary Completion Date
November 30, 2021
Completion Date
May 30, 2023
Last Updated
November 18, 2021
NCT06082518
NCT07221162
NCT06631287
NCT05141058
NCT06679140
NCT06417762
Lead Sponsor
Walvax Biotechnology Co., Ltd.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions